In search of an understanding of pharmaceutical prices

Journal of Research in Pharmaceutical Economics

Volumn 7, Issue 1-2, 1996, Pages 73-88

  Kucukarslan, Suzan ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DRUG COST; HEALTH CARE COST; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0029940864     PISSN: 08966621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Steele H. Patent restrictions and price competition in the ethical drugs industry. J Industrial Econ 1964;12:198-223.
2. U.S. Senate. Subcommittee on Monopoly and Anticompetitive Activities. Competitive problems in the drug industry. Hearings, 14-16 Nov., 1977. Washington, DC: Government Printing Office, 1977.
3. U.S. House. Subcommittee on Investigations and Oversight of the Committee on Science and Technology. Patent term extension and pharmaceutical innovation. Hearings, 4 Feb., 1992. Washington, DC: Government Printing Office.
4. Spivey RN, Trimble AG. Effect of the Drug Price Competition Act on market exclusivity of new drugs: a simulation. Drug Info J 1986;20:27-35.
5. Grabowski HG. Drug regulation and innovation: empirical evidence and policy options. Washington, DC: American Enterprise Institute for Public Policy Research, 1976.
6. Balance R, Pogany J, Forstner H. The world's pharmaceutical industries: an international perspective on innovation, competition and policy. Brookfield, VT: Edward Elgar Publishing Co., 1992.
7. Drug Price Competition Patent Term Restoration Act of 1984 (PL 98-417, 24 Sept. 1984).
8. Rheinstein P, Morrison JC. An FDA view of the ANDA/patent extension law. Pharm Executive 1985;(July):44-6.
9. U.S. House. Subcommittee on Health and the Environment of the Committee on Energy and Commerce. Price increases for prescription drugs and related information (S.Rpt.). July 15, 1985.
10. U.S. House. Subcommittee on Health and the Environment of the Committee on Energy and Commerce. Price increases for prescription drugs and related information (S.Rpt.). April 21, 1987.
11. U.S. Senate. Special Committee on Aging. Prescription drug prices: are we getting our money's worth? (S.Rpt.). July 18, 1989.
12. Coster JM. Medicaid's new prudent purchasing law: a watershed event for pharmacy practice. US Pharm 1991;(Jan):58-61.
13. U.S. General Accounting Office. Medicaid changes in drug prices paid by HMOs and hospitals since enactment of rebate provisions. GAO/HRD-93-43. January 1993.
14. U.S. Senate. Special Committee on Aging. 1993 pharmaceutical price inflation: drug prices for older Americans still increasing much faster than inflation (S.Rpt.). January 1994.
15. Kucukarslan S, Pathak D. The pharmaceutical market's complaining process: an application of Hirschman's theory to a public policy problem. J Consumer Satisfaction/Dissatisfaction Complain Behav. In press.
16. U.S. Senate. Special Committee on Aging. A status report: accessibility and affordability of prescription drugs for older Americans (S.Rpt.). Washington, DC: Government Printing Office, 1992.
17. Enrollment in HMOs spurted almost 10% in 1993 report says. Wall Street J 1993 Dec 10:B11.
18. New era in US pharm industry. SCRIP 1993;(Apr 9/13):18.
19. PCS managed care program will pay pharmacies for generic therapeutic (with MD clearance) substitution. FDC Rep-Pink Sheet 1993;55(46):3-4.
20. Pharmaceutical Manufacturers Association. Facts at a glance. Washington, DC: PMA, 1992.
21. Reekie WD. Price and quality competition in the United States drug industry. J Industrial Econ 1978;26:223-37.
22. Justice Dept denies PMA request for antitrust clearance. FDC Rep-Pink Sheet 1993;55(40):3-4.
23. Tanouye E. SmithKline begins a rebate program for antiulcer drug. Wall Street J 1993 Nov 9:B5.
24. MMD pays one-time sales for Rugby's $280 mil annual sales. FDC Rep-Pink Sheet 1993;55(41):T&G5-6.
25. Tanouye E. Hoechst unit plans to acquire stake in Copley. Wall Street J 1993 Oct 11:A3+.
26. Hoechst-Celanese's $546 mil purchase of 51% of Copley. FDC Rep-Pink Sheet 1993;55(42):3-5.
27. Miles takes a "Schein" to generics. FDC Rep-Pink Sheet 1994;56(8):3-4.
28. Merck-Medco deal won't be challenged on antitrust grounds. Wall Street J 1993 Nov 9:B4.
29. Medco claims to have added clients with 12 mil covered lives. FDC Rep-Pink Sheet 1994;56(8):5-7.
30. Merck-Medco managed care division has staff. FDC Rep-Pink Sheet 1994;56(2):10.
31. Tanouye E. Drug firms share risks with care givers. Wall Street J 1993 Dec 6:B1+.
32. U.S. Senate. 102nd Congress, 1st Session. S. 2000, Prescription Drug Cost Containment Act of 1991.
33. Breakthrough drug review provisions of modified Clinton health reform plan would create council under HHS. FDC Rep-Pink Sheet 1993;55(44):3+.
34. Tanouye E. Drug industry darkens view of Clinton health plan; others predict many pharmaceutical firms will benefit from changes. Wall Street J 1993 Oct 29:B4.
35. Bristol-Myers Squibb's Capoten reinstated on Medi-Cal formulary. FDC Rep-Pink Sheet 1993;55(45):T&G4.
36. Lilly's Prozac and Humulin have exclusive positions in RxCare formulary. FDC Rep-Pink Sheet 1994;56(9):6-7.